An article covering the world’s first commercialization of a federated learning-based AI drug discovery platform—developed by Elix and LINC using AI models trained on data from 16 pharmaceutical companies—was featured in The Nikkan Kogyo Shimbun Digital Edition on July 17, Nikkei Biotech ONLINE on July 15, Biz/Zine on July 11, and introduced in AnswersNews on July 8, 2025.

▼ The Nikkan Kogyo Shimbun Digital Edition
(July 17, 2025 – Japanese only, subscription required)
Elixなど、AI創薬基盤を事業化　16社共同活用
Elix and Others Commercialize AI Drug Discovery Platform in Joint Effort by 16 Companies
https://www.nikkan.co.jp/articles/view/00754924?gnr_footer=0082657

▼ Nikkei Biotech ONLINE (July 15, 2025 – Japanese only, subscription required)
AMEDの創薬AIプロジェクトが事業化、製薬企業16社の創薬関連データを学習
AMED’s Drug Discovery AI Project Commercialized: Learning from Drug Discovery Data of 16 Pharmaceutical Companies
https://bio.nikkeibp.co.jp/atcl/news/p1/25/07/14/13530/

▼ Biz/Zine (July 11, 2025 – Japanese only)
ElixとLINC、製薬企業16社のデータを連合学習したAI創薬プラットフォームを事業化
Commercialization of a Federated Learning-Based AI Drug Discovery Platform Developed by Elix and LINC Using Data from 16 Pharmaceutical Companies
https://bizzine.jp/article/detail/11821

▼ AnswersNews (July 8, 2025 – Japanese only)
ElixとLINC、製薬16社のデータを連合学習したAI創薬プラットフォームを事業化
Elix and LINC Commercialize AI Drug Discovery Platform Developed with Federated Learning Using Data from 16 Pharmaceutical Companies
https://answers.ten-navi.com/pharmanews/30503/